A
Abraham Majluf-Cruz
Researcher at Mexican Social Security Institute
Publications - 110
Citations - 1173
Abraham Majluf-Cruz is an academic researcher from Mexican Social Security Institute. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 15, co-authored 103 publications receiving 988 citations.
Papers
More filters
Journal ArticleDOI
Pancreatic islet amyloidosis, β-cell apoptosis, and α-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons
Rodolfo Guardado-Mendoza,Alberto M. Davalli,Alberto O. Chavez,Gene B. Hubbard,Edward J. Dick,Abraham Majluf-Cruz,Carlos Enrique Tene-Pérez,Lukasz Goldschmidt,John Hart,Carla Perego,Anthony G. Comuzzie,Maria Elizabeth Tejero,Giovanna Finzi,Claudia Placidi,Stefano La Rosa,Carlo Capella,Glenn A. Halff,Amalia Gastaldelli,Ralph A. DeFronzo,Franco Folli +19 more
TL;DR: The results strongly support the concept that IA and β-cell apoptosis in concert with α-cell proliferation and hypertrophy are key determinants of islets of Langerhans “dysfunctional remodeling” and hyperglycemia in the baboon, a nonhuman primate model of type-2 diabetes mellitus.
Journal ArticleDOI
Venous thrombosis among patients with AIDS.
Abraham Majluf-Cruz,Mara Silva-Estrada,Rita Sánchez-Barboza,Guadalupe Montiel-Manzano,Sandra Treviño-Perez,Mario Santoscoy-Gómez,Adriana Ruiz de Chavez-Ochoa,Norma Corona-de la Penña,Leopoldo Nieto-Cisneros +8 more
TL;DR: The data suggest that protease inhibitors could be a risk factor for venous thrombosis not due toThrombophilic abnormalities but likely related to abnormalities in platelets or endothelium.
Journal ArticleDOI
Rituximab therapy for chonic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis
Jaime García-Chávez,Abraham Majluf-Cruz,Laura Montiel-Cervantes,Miriam García-Ruiz Esparza,Jorge Vela-Ojeda +4 more
TL;DR: Rituximab therapy is effective and safe in adult patients with chronic and refractory ITP, and overall response rate achieved is high, long term, and with no risk of adverse events.
Journal ArticleDOI
Hemophagocytic syndrome associated with hematological neoplasias.
Abraham Majluf-Cruz,Rosa Elena Sosa-Camas,Oscar Pérez-Ramı́rez,A Rosas-Cabral,Florencia Vargas-Vorackova,Juan Labardini-Méndez +5 more
TL;DR: It is suggested that the presence of HPS is a negative prognosis factor in patients with HN and an individualized, early, and intensive chemotherapeutic regimen may be required for HN complicated with this syndrome.
Journal ArticleDOI
Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor
Jorge Vela-Ojeda,M. A. García-Ruiz Esparza,Y. Padilla-González,E Sanchez-Cortés,Jaime García-Chávez,Laura Montiel-Cervantes,Laura Montiel-Cervantes,Elba Reyes-Maldonado,Abraham Majluf-Cruz,Hector Mayani +9 more
TL;DR: MM-associated AL represents a poorer prognosis disease even in the absence of symptoms at diagnosis, and this specific association may be considered as an independent high-risk prognostic factor.